BANGKOK (The Nation / ANN): Government spokesman Ratchada Thanadirek released a progress report on Thursday, July 1, on Thailand’s four plans to develop vaccines against Covid-19.
A joint effort of the Government Pharmaceutical Organization (GPO) and the Mahidol University Vaccine Center, the NDV-HXP-S project in phase 1/2 human trials to assess the safety and capacity of the prototype vaccine to stimulate immunity. The volunteers received the vaccine on March 22.
The NDV-HXP-S vaccine will be produced in the GPO plant, which means that no investment is required to build a new plant.
The vaccine uses the same technology as the influenza vaccine and has benefited from international cooperation from the PATH organization with joint research from manufacturers in Vietnam and Brazil.
The prototype developed by the Vaccine Research Center at Chulalongkorn University Faculty of Medicine is an mRNA vaccine that uses the same manufacturing technology as the Pfizer and Moderna vaccines.
The prototype generated a high immune response in rats and monkeys before the start of phase 1 human trials on 72 volunteers on June 14.
ChulaCov19 vaccine can be stored at refrigerated temperatures of 2 to 8 ° C for up to 3 months and at room temperature (25 ° C) for up to 2 weeks.
Covigen produced by Bionet-Asia Plc stimulated a strong immune response in rats. Approval is now sought from the Food and Drug Administration (FDA) for phase 1 human trials with a parallel trial in Australia.
Baiya Phytopharm, a start-up at the CU Innovation Hub at Chulalongkorn University, modifies the protein in tobacco to mimic the Covid-19 virus. It will start testing its prototype vaccine in humans in August or September.